Hinterbrandner, Magdalena; Rubino, Viviana; Stoll, Carina; Forster, Stefan; Schnüriger, Noah Samuel; Radpour, Ramin; Bärlocher, Gabriela M.; Ochsenbein, Adrian F.; Riether, Carsten
(2021).
Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells.
JCI insight, 6(23)
JCI Insight
10.1172/jci.insight.151797
Leukemia stem cells (LSCs) promote the disease and seem resistant to therapy and immune control. Why LSCs are selectively resistant against elimination by cytotoxic CD8+ T cells (CTLs) is still unknown. In this study, we demonstrate that LSCs in chronic myeloid leukemia (CML) can be recognized and killed by CD8+ CTLs in vitro. However, Tregs, which preferentially localized close to CD8+ CTLs in CML bone marrow (BM), protected LSCs from MHC-class I dependent CD8+ CTL-mediated elimination in vivo. BM Tregs in CML were characterized by the selective expression of tumor necrosis factor receptor 4 (Tnfrsf4). Stimulation of Tnfrsf4-signaling did not deplete Tregs but reduced the capacity of Tregs to protect LSCs from CD8+ CTL-mediated killing. In the BM of newly diagnosed CML patients, TNFRSF4 mRNA levels were significantly increased and correlated with the expression of the Treg-restricted transcription factor FOXP3. Overall, these results identify Tregs as key regulator of immune escape of LSCs and TNFRSF4 as a potential target to reduce the function of Tregs and boost anti-leukemic immunity in CML.
Interest & Impact
Downloads
81 since deposited on 01 Dec 2021
31 in the past 12 months
Citations
5 Citations in Web of Science ®
6 Citations in Scopus
Search
in Google Scholar™
Services
Actions (login required)
|
Edit item |
Item Type: |
Journal Article
(Original Article)
|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Tumor-Immunologie 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Tumor-Immunologie 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Med. Onkologie / Hämatologie (Erw.) 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Med. Onkologie / Hämatologie (Erw.) 04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) |
Graduate School: |
Graduate School for Cellular and Biomedical Sciences (GCB) |
UniBE Contributor: |
Hinterbrandner, Magdalena, Rubino, Viviana, Stoll, Carina Manon, Forster, Stefan, Schnüriger, Noah Samuel, Radpour, Ramin, Bärlocher, Gabriela Maria, Ochsenbein, Adrian, Riether, Carsten |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2379-3708 |
Publisher: |
JCI Insight |
Language: |
English |
Submitter: |
Rebeka Gerber
|
Date Deposited: |
01 Dec 2021 11:46 |
Last Modified: |
28 Mar 2024 14:09 |
Publisher DOI: |
10.1172/jci.insight.151797 |
PubMed ID: |
34727093 |
Uncontrolled Keywords: |
Cancer immunotherapy Hematology Leukemias Stem cells |
BORIS DOI: |
10.48350/160879 |
URI: |
https://boris.unibe.ch/id/eprint/160879 |
|
|
|
|
Actions (login required)
|
Edit item |